Trevi Therapeutics Reports Q1 2025 Results and Updates

Trevi Therapeutics ( (TRVI) ) has released its Q1 earnings. Here is a breakdown of the information Trevi Therapeutics presented to its investors.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing Haduvio, an investigational therapy for chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). The company operates within the biopharmaceutical sector and is notable for its unique approach targeting opioid receptors to manage chronic cough.

In its latest earnings report, Trevi Therapeutics announced the completion of patient enrollment and visits for the Phase 2b CORAL trial in IPF patients with chronic cough, with results expected in the second quarter of 2025. Additionally, the company reported positive topline results from the Phase 2a RIVER trial in RCC patients, showcasing a significant reduction in cough frequency.

Key financial metrics from the first quarter of 2025 include a decrease in research and development expenses to $7.8 million, attributed to reduced clinical development costs, while general and administrative expenses rose to $3.7 million due to increased personnel-related expenses. Trevi ended the quarter with $103.3 million in cash and equivalents, ensuring a cash runway into the fourth quarter of 2026.

The company reported a net loss of $10.3 million for the quarter, a slight improvement from the $10.9 million loss in the same period of 2024. Despite the loss, Trevi remains financially stable with a strong balance sheet to support ongoing development efforts.

Looking ahead, Trevi Therapeutics is poised to advance its clinical trials and further explore the potential of Haduvio in treating chronic cough conditions, with management expressing optimism about upcoming trial results and the company’s strategic direction.